New AlphaMedix data showed sustained and clinically meaningful responses across both RLT-naïve and RLT-exposed patients with unresectable or metastatic GEP-NETsFirst phase 2 study to evaluate TAT with ...
Discusses ESMO Data on TGF-beta Receptor by PD-1 Bispecific in Colorectal Cancer and G12D Inhibitor in Pancreatic ...
Shares of Perspective Therapeutics (CATX) are down $1.52, or 34%, to $2.97 after the radiopharmaceutical company announced that updated interim ...
Discover ATAI’s pipeline, including promising BPL-003 for TRD, upcoming Phase 3 trials, and a merger with Beckley Psytech.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback